These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21040364)

  • 1. Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system.
    Raymundo EM; Rice KR; Chen Y; Zhao J; Brassell SA
    BJU Int; 2011 Apr; 107(8):1216-22. PubMed ID: 21040364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study.
    Amini E; Palmer TC; Cai J; Lieskovsky G; Daneshmand S; Djaladat H
    World J Urol; 2018 Aug; 36(8):1233-1239. PubMed ID: 29536157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
    Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
    BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.
    Pierorazio PM; Walsh PC; Partin AW; Epstein JI
    BJU Int; 2013 May; 111(5):753-60. PubMed ID: 23464824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Lance R; Kusuda L; Donahue T; Foley J; Chung A; Sexton W; Soderdahl D; Rich NM
    Surgery; 2002 Aug; 132(2):213-9. PubMed ID: 12219014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.
    Yossepowitch O; Eggener SE; Serio AM; Carver BS; Bianco FJ; Scardino PT; Eastham JA
    Eur Urol; 2008 May; 53(5):950-9. PubMed ID: 17950521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
    Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR
    BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of surgical margin status on prostate-cancer-specific mortality.
    Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
    BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.
    Pierorazio PM; Ross AE; Lin BM; Epstein JI; Han M; Walsh PC; Partin AW; Pavlovich CP; Schaeffer EM
    BJU Int; 2012 Oct; 110(8):1122-8. PubMed ID: 22373045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database.
    Bañez LL; Terris MK; Aronson WJ; Presti JC; Kane CJ; Amling CL; Freedland SJ
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1208-12. PubMed ID: 19336564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention.
    Sakr WA
    Eur Urol; 1999; 35(5-6):474-8. PubMed ID: 10325508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE.
    Latini DM; Elkin EP; Cooperberg MR; Sadetsky N; Duchane J; Carroll PR
    Cancer; 2006 Feb; 106(4):789-95. PubMed ID: 16400651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial differences in prostate cancer treatment outcomes: a systematic review.
    Peters N; Armstrong K
    Cancer Nurs; 2005; 28(2):108-18. PubMed ID: 15815180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Socioeconomic and clinical factors influence the interval between positive prostate biopsy and radical prostatectomy.
    Pitman M; Korets R; Kates M; Hruby GW; McKiernan JM
    Urology; 2012 Nov; 80(5):1027-32. PubMed ID: 23107396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.